Esperion Therapeutics Inc
NASDAQ:ESPR

Watchlist Manager
Esperion Therapeutics Inc Logo
Esperion Therapeutics Inc
NASDAQ:ESPR
Watchlist
Price: 0.90865 USD 6.93%
Market Cap: 180m USD

Intrinsic Value

The intrinsic value of one ESPR stock under the Base Case scenario is 4.7807 USD. Compared to the current market price of 0.90865 USD, Esperion Therapeutics Inc is Undervalued by 81%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ESPR Intrinsic Value
4.7807 USD
Undervaluation 81%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Esperion Therapeutics Inc

Valuation History Unavailable

Historical valuation for ESPR cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ESPR?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Esperion Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Esperion Therapeutics Inc

Current Assets 318.8m
Cash & Short-Term Investments 114.6m
Receivables 81.3m
Other Current Assets 122.9m
Non-Current Assets 5.3m
PP&E 5.2m
Intangibles 56k
Efficiency

Free Cash Flow Analysis
Esperion Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Esperion Therapeutics Inc

Revenue
259.6m USD
Cost of Revenue
-90.1m USD
Gross Profit
169.5m USD
Operating Expenses
-264.4m USD
Operating Income
-94.9m USD
Other Expenses
-58.3m USD
Net Income
-153.2m USD
Fundamental Scores

ESPR Profitability Score
Profitability Due Diligence

Esperion Therapeutics Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Exceptional 3-Years Revenue Growth
Exceptional ROE
48/100
Profitability
Score

Esperion Therapeutics Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

ESPR Solvency Score
Solvency Due Diligence

Esperion Therapeutics Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
43/100
Solvency
Score

Esperion Therapeutics Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ESPR Price Targets Summary
Esperion Therapeutics Inc

There are no price targets for ESPR.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Esperion Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ESPR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ESPR Insider Trading
Buy and sell transactions by insiders

ESPR News

Other Videos
What is the Intrinsic Value of one ESPR stock?

The intrinsic value of one ESPR stock under the Base Case scenario is 4.7807 USD.

Is ESPR stock undervalued or overvalued?

Compared to the current market price of 0.90865 USD, Esperion Therapeutics Inc is Undervalued by 81%.

Back to Top